Clinical Immunotherapeutics

, Volume 1, Issue 4, pp 307–318 | Cite as

Antiadhesion Peptides in the Prevention of Tumour Metastasis

  • Ikuo Saiki
Review Article Disease Treatment Review


The adhesive interaction between tumour cells and host cells or the extracellular matrix plays a crucial role in metastasis formation. We have used synthetic or recombinant polypeptide analogues, such as poly(RGD), based on the Arg-Gly-Asp (RGD) sequence found in fibronectin, or CH-271, based on functional domains in fibronectin, to regulate the mechanisms involved in cell adhesion during the metastatic process. Poly(RGD) inhibited experimental lung and liver metastasis effectively when coinjected intravenously with various types of tumours. In a model of spontaneous lung metastasis using the B16-BL6 melanoma, repeated administration of this polypeptide before or after surgical excision of the primary tumour resulted in a significant inhibition of tumour metastasis without affecting the growth of the primary tumour, and substantially prolonged the survival time of mice. The mechanism responsible for the inhibition of tumour metastasis by the polypeptides is at least partly associated with the ability to interfere with cellular functions such as adhesiveness, motility and invasiveness in the process of metastasis. Coadministration of the CH-271 fusion polypeptide and anticancer drugs, i.e. antiadhesion therapy combined with chemotherapy, caused a dramatic inhibition of lung and liver metastasis of tumours as compared with either treatment alone or with the control. Since the polypeptides derived from cell adhesion molecules show no short term toxicity to the host, they may provide a new and promising approach for the control and prevention of cancer metastasis.


Adis International Limited Laminin Tumour Metastasis Metastatic Melanoma Cell Inhibit Tumour Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fidler IJ. The evolution of biological heterogeneity in metastatic neoplasms. In: Nicolson GL, Milas L, editors. Cancer invasion and metastases: biologic and therapeutic aspects. New York: Raven Press, 1984: 5–26Google Scholar
  2. 2.
    Nicolson GL. Tumour cell instability, diversification, and progression to the metastatic phenotype from oncogene to oncofetal expression. Cancer Res 1987; 47: 1473–87PubMedGoogle Scholar
  3. 3.
    Hart IR. Seed and soil revisited: mechanisms of site specific metastasis. Cancer Metastasis Rev 1982; 1: 5–16PubMedCrossRefGoogle Scholar
  4. 4.
    Liotta LA, Rao CV, Barsky SH. Tumour invasion and the extracellular matrix. Lab Invest 1983; 49: 636–49PubMedGoogle Scholar
  5. 5.
    Terranova VP, Hujanen ES, Martin GR. Basement membrane and the invasive activity of metastatic tumour cells. J Natl Cancer Inst 1986; 77: 311–6PubMedGoogle Scholar
  6. 6.
    McCarthy JB, Furcht LT. Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro. J Cell Biol 1984; 98: 1474–80PubMedCrossRefGoogle Scholar
  7. 7.
    Karpathlan S, Perlstein E. Heterogenous mechanism of tumour cell-induced platelet aggregation with possible strategy toward prevention of metastases. In: Honn KV, Sloane BF, editors. Hemostasis Mechanisms and Metastasis. Boston: Martinus Nijhoff, 1984: 139–69Google Scholar
  8. 8.
    Kornblihtt AR, Umezaka K, Vibe-Pedersan K, et al. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 1985; 4: 1755–9PubMedGoogle Scholar
  9. 9.
    Suzuki S, Oldberg A, Hayman EG, et al. Complete amino acid sequence of human vitronectin deduced from cDNA: similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519–24PubMedGoogle Scholar
  10. 10.
    Sasaki M, Kato S, Kohno K, et al. Sequence of the cDNA encoding the laminin B1 chain reveals a multidomain protein containing cystein rich repeats. Proc Natl Acad Sci USA 1987; 84: 935–8PubMedCrossRefGoogle Scholar
  11. 11.
    Sasaki M, Yamada Y. The laminin B2 chain has multidomain structure homologous to the B1 chain. J Biol Chem 1987; 262: 17111–7PubMedGoogle Scholar
  12. 12.
    Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1982; 309: 30–3CrossRefGoogle Scholar
  13. 13.
    Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 517–8PubMedCrossRefGoogle Scholar
  14. 14.
    Graf J, Iwamoto Y, Sasaki M, et al. Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 1987; 48: 989–96PubMedCrossRefGoogle Scholar
  15. 15.
    Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491–7PubMedCrossRefGoogle Scholar
  16. 16.
    Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1454–5CrossRefGoogle Scholar
  17. 17.
    Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425–34PubMedCrossRefGoogle Scholar
  18. 18.
    Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549–54PubMedCrossRefGoogle Scholar
  19. 19.
    Springer TA, Lasky LA. Cell adhesion. Sticky sugars for selectins. Nature 1991; 349: 196–7PubMedCrossRefGoogle Scholar
  20. 20.
    Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4: 2868–80PubMedGoogle Scholar
  21. 21.
    Barsky SH, Rao CN, Williams JE, et al. Laminin molecular domains which alter metastasis in a murine model. J Clin Invest 1984; 74: 843–8PubMedCrossRefGoogle Scholar
  22. 22.
    Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467–70PubMedCrossRefGoogle Scholar
  23. 23.
    Iwamoto Y, Robey FA, Graf J, et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987; 238: 1132–4PubMedCrossRefGoogle Scholar
  24. 24.
    Cheresh DA, Pytela R, Pierschbacher MD, et al. An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in the divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol 1987; 105: 1163–73PubMedCrossRefGoogle Scholar
  25. 25.
    Dedhar S, Argraves WS, Suzuki S, et al. Human osteosarcoma cells resistant to detachment by an Arg-Gly-Asp-containing peptide overproduce the fibronectin receptor. J Cell Biol 1987; 105: 1175–82PubMedCrossRefGoogle Scholar
  26. 26.
    Wewer UM, Traboletti G, Sobel ME, et al. Role of laminin receptor in tumour cell migration. Cancer Res 1987; 47: 5681–98Google Scholar
  27. 27.
    McCarthy JB, Skubitz AP, Palm SL, et al. Metastasis inhibition of different tumour types by purified laminin fragments and a heparin-binding fragment of fibronectin. J Natl Cancer Inst. 1988; 80: 108–16PubMedCrossRefGoogle Scholar
  28. 28.
    Saiki I, Murata J, Iida J, et al. Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences. Br J Cancer 1989; 59: 194–7PubMedCrossRefGoogle Scholar
  29. 29.
    Saiki I, Iida J, Murata J, et al. Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules. Cancer Res 1989; 49: 3815–22PubMedGoogle Scholar
  30. 30.
    Saiki I, Murata J, Iida J, et al. The inhibition of murine lung metastasis by synthetic polypeptides [poly (arg-gly-asp) and poly (tyr-ile-gly-ser-arg)] with a core sequence of cell adhesion molecules. Br J Cancer 1989; 60: 722–8PubMedCrossRefGoogle Scholar
  31. 31.
    Saiki I, Murata J, Matsuno K, et al. Anti-metastatic and anti-invasive effects of polymeric Arg-Gly-Asp (RGD) peptide, poly(RGD), and its analogues. Jpn J Cancer Res 1990; 81: 660–7PubMedCrossRefGoogle Scholar
  32. 32.
    Humphries MJ, Yamada KM, Olden K. Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest 1988; 81: 782–90PubMedCrossRefGoogle Scholar
  33. 33.
    Murata J, Saiki I, Ogawa R, et al. Molecular properties of poly(RGD) and its binding capacities to metastatic melanoma cells. Int J Pept Protein Res 1991; 38: 212–7PubMedCrossRefGoogle Scholar
  34. 34.
    Ugen KE, Mahalingan M, Klein PA, et al. Inhibition of tumour cell-induced platelet aggregation and experimental tumor metastasis by the synthetic Gly-Arg-Gly-Asp-Ser peptide. J Natl Cancer Inst 1988; 80: 1461–6PubMedCrossRefGoogle Scholar
  35. 35.
    Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–8PubMedCrossRefGoogle Scholar
  36. 36.
    Schor AM, Schor SL. Tumour angiogenesis. J Pathol 1983; 141: 385–413PubMedCrossRefGoogle Scholar
  37. 37.
    Folkman J. Tumour angiogenesis. Adv Cancer Res 1985; 43: 175–203PubMedCrossRefGoogle Scholar
  38. 38.
    Saiki I, Murata J, Makabe T, et al. Inhibition of tumour angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD). Jpn J Cancer Res 1990; 81: 668–75PubMedCrossRefGoogle Scholar
  39. 39.
    McCarthy JB, Hagen ST, Furcht LT. Human plasma fibronectin contains multiple adhesion- and motility-promoting domains for metastatic melanoma cells. J Cell Biol 1986; 102: 179–88PubMedCrossRefGoogle Scholar
  40. 40.
    Saiki I, Matsumoto Y, Murata J, et al. Recombinant fusion polypeptide with cell- and heparin-binding domains of fibronectin inhibits liver metastasis of L5178Y-ML25 lymphoma cells. Jpn J Cancer Res 1991; 82: 1120–9PubMedCrossRefGoogle Scholar
  41. 41.
    Matsumoto Y, Saiki I, Makabe T, et al. Inhibitory effect of antimetastatic fusion polypeptide of human fibronectin on tumour cell adhesion to extracellular matrices. Jpn J Cancer Res 1991; 82: 1130–8PubMedCrossRefGoogle Scholar
  42. 42.
    Saiki I, Murata J, Makabe T, et al. Inhibition of lung metastasis by synthetic and recombinant fragments of human fibronectin with functional domains. Jpn J Cancer Res 1990; 81: 1003–10PubMedGoogle Scholar
  43. 43.
    Saiki I, Makabe T, Yoneda J, et al. Inhibitory effect of fibronectin and its recombinant polypeptides on the adhesion of metastatic melanoma cells to laminin. Jpn J Cancer Res 1991; 82: 1112–9PubMedCrossRefGoogle Scholar
  44. 44.
    Makabe T, Saiki I, Murata J, et al. Modulation of haptotactic migration of metastatic melanoma cells by the interaction between heparin and haparin-binding domain of fibronectin. J Biol Chem 1990; 265: 14270–6PubMedGoogle Scholar
  45. 45.
    Saiki I, Yoneda J, Kobayashi H, et al. Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn J Cancer Res 1993; 84: 326–35PubMedCrossRefGoogle Scholar
  46. 46.
    Murata J, Saiki I, Nishimura S, et al. Inhibitory effect of chitin heparinoids on the lung metastasis of B16-BL6 melanoma. Jpn J Cancer Res 1989; 80: 866–72PubMedCrossRefGoogle Scholar
  47. 47.
    Murata J, Saiki I, Matsuno K, et al. Inhibition of tumour cell arrest in lungs by antimetastatic chitin heparinoid. Jpn J Cancer Res 1990; 81: 506–13PubMedCrossRefGoogle Scholar
  48. 48.
    Saiki I, Murata J, Nakajima M, et al. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res 1990; 50: 3631–7PubMedGoogle Scholar
  49. 49.
    Murata J, Saiki I, Makabe T, et al. Inhibition of tumour-induced angiogenesis by sulfated chitin derivatives. Cancer Res 1991; 51: 21–6Google Scholar
  50. 50.
    Saiki I, Yoneda J, Igarashi Y, et al. Antimetastatic activity of polymeric RGDT peptides conjugated with poly(ethylene glycol). Jpn J Cancer Res 1993; 84: 558–65PubMedCrossRefGoogle Scholar
  51. 51.
    Kumagai H, Tajima M, Ueno Y, et al. Effect of cyclic RGD peptide on cell adhesion and tumour metastasis. Biochem Biophys Res Commun 1991; 177: 74–82PubMedCrossRefGoogle Scholar
  52. 52.
    Komazawa H, Saiki I, Igarashi Y, et al. Inhibition of tumour metastasis by a synthetic polymer containing a cell-adhesive RGDS peptide conjugate. J Bioactive Compatible Polymers 1993; 8: 259–74CrossRefGoogle Scholar
  53. 53.
    Komazawa H, Saiki I, Igarashi Y, et al. The conjugation of RGDS peptide with CM-chitin augments the peptide-mediated inhibition of tumour metastasis. Carbohydrate Polymer 1993; 21. In pressGoogle Scholar
  54. 54.
    Komazawa H, Saiki I, Nishikawa N, et al. Inhibition of tumour metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS. Clin Exp Metastasis 1993. In press.Google Scholar
  55. 55.
    Komazawa H, Saiki I, Aoki M, et al. Synthetic Arg-Gly-Asp-Ser analogues of cell recognition site of fibronectin that retain antimetastatic and anti-cell adhesive properties. Biol Pharm Bull 1993; 16: 997–1003PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Ikuo Saiki
    • 1
  1. 1.Research Institute for Traditional Sino-Japanese MedicinesToyama Medical and Pharmaceutical UniversityToyamaJapan

Personalised recommendations